These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease. Markham A; Benfield P CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755 [TBL] [Abstract][Full Text] [Related]
4. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614 [TBL] [Abstract][Full Text] [Related]
5. Pergolide and lisuride in advanced Parkinson's disease. Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627 [TBL] [Abstract][Full Text] [Related]
6. Dopamine agonists in the treatment of Parkinson's disease. Rinne UK Adv Neurol; 1983; 37():141-50. PubMed ID: 6305175 [TBL] [Abstract][Full Text] [Related]
7. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease. Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182 [TBL] [Abstract][Full Text] [Related]
8. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. Im JH; Ha JH; Cho IS; Lee MC J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782 [TBL] [Abstract][Full Text] [Related]
10. Dopamine agonists as primary treatment in Parkinson's disease. Rinne UK Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394 [No Abstract] [Full Text] [Related]
11. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141 [TBL] [Abstract][Full Text] [Related]
12. An open label trial of pergolide in Thai patients with Parkinson's disease. Poungvarin N; Prayoonwiwat N; Devahasatin V; Viriyavejakul A J Med Assoc Thai; 1996 Apr; 79(4):205-9. PubMed ID: 8708504 [TBL] [Abstract][Full Text] [Related]
13. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias. Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640 [TBL] [Abstract][Full Text] [Related]
14. Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum? Melamed E J Neural Transm Suppl; 1995; 45():57-60. PubMed ID: 8748609 [TBL] [Abstract][Full Text] [Related]
15. Pergolide and Parkinson's disease: new preparation. No clear benefit. Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497 [TBL] [Abstract][Full Text] [Related]
16. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. Kondo T J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060 [TBL] [Abstract][Full Text] [Related]
20. [Lisuride in the combination treatment of Parkinson disease]. Jellinger K Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]